Safety and Efficacy Study in NTG, POAG, Glaucoma Suspect, Ocular Hypertension Patients With Diagnosed Prostaglandin Associated Peri-orbitopathy Switching From Preserved Prostaglandin Analogues Monotherapy to Omidenepag Isopropyl
This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.
the investigators would like to confirm the real world evidence(RWE) of safety and efficacy after changing to Eybelis ophthalmic solution 0.002%.
100 Clinical Results associated with Santen Pharmaceutical Asia Pte Ltd.
0 Patents (Medical) associated with Santen Pharmaceutical Asia Pte Ltd.
100 Deals associated with Santen Pharmaceutical Asia Pte Ltd.
100 Translational Medicine associated with Santen Pharmaceutical Asia Pte Ltd.